- Multimeric Anti-DR5 IgM Agonist Antibody IGM-8444 Is a Potent Inducer of Cancer Cell Apoptosis and Synergizes with Chemotherapy and BCL-2 Inhibitor ABT-199
Beatrice T. Wang et al, 2021, Molecular Cancer Therapeutics CrossRef - Inhibition of the mitochondrial pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase by doxorubicin and brequinar sensitizes cancer cells to TRAIL-induced apoptosis
T He et al, 2014, Oncogene CrossRef - Core Fucosylation Mediated by the FucT-8 Enzyme Affects TRAIL-Induced Apoptosis and Sensitivity to Chemotherapy in Human SW480 and SW620 Colorectal Cancer Cells
Rubén López-Cortés et al, 2023, International Journal of Molecular Sciences CrossRef - Efficient treatment of colon cancer with codelivery of TRAIL and imatinib by liposomes
Rongrong Fu et al, 2024, Pharmaceutical Development and Technology CrossRef - Co-delivery of chemotherapeutics and proteins for synergistic therapy
Chaoliang He et al, 2016, Advanced Drug Delivery Reviews CrossRef - TRAIL mutant membrane penetrating peptide alike (TMPPA) TRAIL-Mu3 enhances the antitumor effects of TRAIL in vitro and in vivo
Hong Zhu et al, 2017, Molecular Medicine Reports CrossRef - Targeting death receptors for TRAIL by agents designed by Mother Nature
Sahdeo Prasad et al, 2014, Trends in Pharmacological Sciences CrossRef - Antimicrobial Peptides as New Combination Agents in Cancer Therapeutics: A Promising Protocol against HT-29 Tumoral Spheroids
Mina Raileanu et al, 2020, International Journal of Molecular Sciences CrossRef - The Synergistic Effects of Low Dose Fluorouracil and TRAIL on TRAIL-Resistant Human Gastric Adenocarcinoma AGS Cells
Hong Zhu et al, 2013, BioMed Research International CrossRef